| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-48 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-57 |
| filingDate |
2002-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b533eca8630d292889f15427dbce4263
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21de6793e990ea4ef4e3d0db4066002b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1cd5592c3478d06295f7fb8808c0195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4b4e94727b1691dbf0b9a44f9e70ecd |
| publicationDate |
2005-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HU-0402160-A2 |
| titleOfInvention |
T-cell epitopes in carboxypeptidase-G2 |
| abstract |
The present invention relates primarily to polypeptides having therapeutic effects for administration to humans. The polypeptides of the invention are modified polypeptides, wherein the modification results in a reduced tendency of the polypeptide to elicit an immune response when administered to a human subject. In particular, the invention relates to enzymatic modification of bacterial carboxypeptidase G2 (CPG2) to produce CPG2 proteins that are substantially non-immunogenic or less immunogenic than any suitable unmodified enzyme when used in vivo. The invention also provides T cell epitope peptides derived from said unmodified protein; which can be used as a means to produce immunogenic, modified CPG2 variants. SHE |
| priorityDate |
2001-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |